Literature DB >> 30825834

The anti-fibrotic role of mast cells in the liver is mediated by HLA-G and interaction with hepatic stellate cells.

Laurence Amiot1, Nicolas Vu2, Bernard Drenou3, Maurice Scrofani4, Arnaud Chalin2, Christelle Devisme2, Michel Samson2.   

Abstract

BACKGROUND & AIMS: We have reported a significant association between HLA-G expression or the number of hepatic mast cells and liver fibrosis. Here, we investigated the role of HLA-G and mast cells in liver fibrosis, focusing, in particular, on interactions between human mast and stellate cells.
METHODS: Human mast cells (HMC cell line, CD34-derived mast cells, or tissue-derived mast cells) were co-cultured with purified human hepatic stellate cells (HSCs), and collagen I production by HSCs was evaluated. Mast cells and HSCs were characterized by immunocytochemistry. Various conditions were tested: different times in direct or indirect contact, presence or absence of cytokines, addition or not of HLA-G, and presence or absence of specific protease inhibitors.
RESULTS: The reciprocal interaction between HSCs and mast cells led to the attraction of mast cells to HSCs in vivo and in vitro, and to a significant decrease in collagen production, at all times of co-culture, following the direct or indirect contact of mast cells with HSCs alone or in the presence of TGF-β, IFN-α or IL-10. We identified the diffusible factors involved in collagen I degradation as mast cell proteases. Moreover, HLA-G expression increased during the co-culture of HSCs and mast cells, with HLA-G acting on both mast cells and HSCs, to enhance collagen I degradation.
CONCLUSIONS: Mast cells play a beneficial, anti-fibrotic role in liver fibrosis, via the HLA-G-mediated decrease of collagen I. These findings are consistent with high levels of cross-communication between mast cells and hepatic stellate cells and the role of HLA-G.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Fibrosis; HLA-G; Hepatic stellate cells; Mast cells

Mesh:

Substances:

Year:  2019        PMID: 30825834     DOI: 10.1016/j.cyto.2019.02.002

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Higher Mast Cell Accumulation in Human Adipose Tissues Defines Clinically Favorable Obesity Sub-Phenotypes.

Authors:  Nir Goldstein; Yarden Kezerle; Yftach Gepner; Yulia Haim; Tal Pecht; Roi Gazit; Vera Polischuk; Idit F Liberty; Boris Kirshtein; Ruthy Shaco-Levy; Matthias Blüher; Assaf Rudich
Journal:  Cells       Date:  2020-06-20       Impact factor: 6.600

Review 2.  Mast Cells in Liver Fibrogenesis.

Authors:  Ralf Weiskirchen; Steffen K Meurer; Christian Liedtke; Michael Huber
Journal:  Cells       Date:  2019-11-13       Impact factor: 6.600

Review 3.  A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis.

Authors:  Traci A Wilgus; Sara Ud-Din; Ardeshir Bayat
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

4.  HLA-G Is Widely Expressed by Mast Cells in Regions of Organ Fibrosis in the Liver, Lung and Kidney.

Authors:  Nicolas Mouchet; Nicolas Vu; Bruno Turlin; Nathalie Rioux-Leclercq; Stéphane Jouneau; Michel Samson; Laurence Amiot
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

5.  Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy.

Authors:  Ning Li; Kangkang Yu; Minhui Dong; Jinyu Wang; Feifei Yang; Haoxiang Zhu; Jie Yu; Jingshu Yang; Wentao Xie; Bidisha Mitra; Richeng Mao; Feizhen Wu; Haitao Guo; Jiming Zhang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

Review 6.  Exploring the role of mast cells in the progression of liver disease.

Authors:  Shizhuan Huang; Haotian Wu; Feng Luo; Bin Zhang; Tianwei Li; Zongrui Yang; Bixuan Ren; Wenze Yin; Dehai Wu; Sheng Tai
Journal:  Front Physiol       Date:  2022-09-13       Impact factor: 4.755

7.  In Patients With Obesity, the Number of Adipose Tissue Mast Cells Is Significantly Lower in Subjects With Type 2 Diabetes.

Authors:  David Lopez-Perez; Anaïs Redruello-Romero; Jesús Garcia-Rubio; Carlos Arana; Luis A Garcia-Escudero; Francisco Tamayo; Jose D Puentes-Pardo; Sara Moreno-SanJuan; Javier Salmeron; Armando Blanco; Julio Galvez; Josefa Leon; Ángel Carazo
Journal:  Front Immunol       Date:  2021-05-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.